TABLE 1.
Basic characteristics of included articles.
| References | Language | Country | Diagnostic criteria | Psychological disorders | Number of research centers | Sample size (T:C) | Sex ratio (male: female) | Durations | Follow-up | Outcomes | Adverse events (T:C) |
| CHM vs. placebo | |||||||||||
| Zhao and Gan, 2005 | English | China | Rome III | HAMD > 20; HAMA > 14 | 1 | 43 (30:13) | 43 (16:27) | 8 weeks | NR | ①②③④ | 0 |
| Du et al., 2014 | English | China | Rome III | Depression | 1 | 180 (90:90) | NR | 8 weeks | 6 months | ①③⑤ | 0 |
| Tominaga et al., 2018 | English | Japan | Rome III | HADS < 10 | 56 | 118 (61:57) | 125 (36:89) | 8 weeks | NR | ①②③ | 4 (3:1) |
| Chen et al., 2020 | English | China | Rome III | HAMD > 20; HAMA > 14 | 9 | 141 (70:71) | 141 (107:3) | 4 weeks | 4 weeks | ②③④ | 4 (3:1) |
| Zhu and Gu’s (2017) | Chinese | China | Rome III | Mild to moderate depression on the HAMD-17 | 1 | 80 (48:32) | 80 (37:43) | 6 weeks | NR | ②③ | 15 (8:7) |
| CHM vs. mosapride/domperidone + deanxit | |||||||||||
| Han and Wang, 2011 | Chinese | China | Rome III | HAMD ≥ 17 | 1 | 60 (30:30) | 60 (20:40) | 4 weeks | NR | ①③ | NR |
| Lu and Chen, 2011 | Chinese | China | Rome III | HAMA > 7; HAMD > 7 | 1 | 55 (31:24) | 55 (19:36) | 4 weeks | NR | ①③④ | NR |
| Xi et al., 2014 | Chinese | China | Rome III | HAMD ≥ 8 | 1 | 96 (48:48) | 96 (39:57) | 30 days | 6 months | ①③⑤ | 0 |
| Zhang, 2014 | Chinese | China | Rome III | HAMD ≥ 7 | 1 | 70 (35:35) | 70 (29:41) | 30 days | 3 months | ①③⑤ | 3 (0:3) |
| Zhang et al., 2016, 2017a,b,c | Chinese | China | Rome III | HAMD > 20; HAMA > 14 | 1 | 119 (60:59) | 119 (49:70) | 4 weeks | NR | ①③④ | Incomplete information |
| Li et al., 2018 | Chinese | China | Rome III | HAMD ≥ 20; HAMA ≥ 14 | 1 | 80 (40:40) | 80 (34:46) | 4 weeks | NR | ①③④⑤ | 0 |
T, treatment group; C, control group; NR, not report. ① Total efficiency, ② total symptom score, ③ depression scale, ④ HAMA score, and ⑤ gastric emptying rate.